Skip to main content
Valiant Laboratories Limited logo

Valiant Laboratories Limited — Investor Relations & Filings

Ticker · VALIANTLAB ISIN · INE0JWS01017 LEI · 335800VKNJKWJ4LD6855 BSE.NS Manufacturing
Open in API
Filings indexed 173 across all filing types
Latest filing 2026-05-30 Legal Proceedings Report
Country IN India
Listing BSE.NS VALIANTLAB

About Valiant Laboratories Limited

https://www.valiantlabs.in/

Valiant Laboratories Limited specializes in the manufacturing of Active Pharmaceutical Ingredients (APIs) and bulk drugs, with a primary focus on the production of Paracetamol. The company operates dedicated manufacturing facilities designed for the large-scale synthesis of analgesic and antipyretic compounds. By maintaining rigorous quality control standards and process efficiencies, it serves as a key supplier for formulations across various therapeutic segments. Its core business activities encompass the chemical processing and distribution of high-grade medicinal ingredients, catering to a diverse range of healthcare manufacturers. The organization prioritizes technical excellence in API synthesis and the optimization of production workflows to ensure a consistent supply of essential pharmaceutical components.

Recent filings

Filing Released Lang Actions
Action(s) taken or orders passed
Legal Proceedings Report Classification · 87% confidence The document is an intimation under SEBI Listing Regulations (Regulation 30) notifying stock exchanges of a tax authority order (GST demand and penalties). It is a disclosure of a regulatory action/legal matter rather than an earnings release, financial report, board change, or share transaction. This falls under an update on regulatory/legal proceedings affecting the company.
2026-05-30 English
Please find enclosed
Legal Proceedings Report Classification · 82% confidence The document is an exchange intimation under SEBI Listing Regulations (Regulation 30), disclosing receipt of a GST order from a tax authority, detailing a regulatory/legal action against the company. It is neither a financial report nor a meeting or dividend notice but a legal/regulatory update. This matches the “Legal Proceedings Report” category (LTR).
2026-05-30 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings Classification · 82% confidence The document is a compliance declaration filed under SEBI Regulation 31(4) regarding promoter share encumbrance as of the financial year‐end. It does not contain financial statements or results, nor is it announcing a report publication or an earnings release. It is a routine regulatory compliance filing, not a threshold‐crossing major shareholding notice (which would specify a change in ownership levels) but rather a general statutory declaration. This fits the ‘Regulatory Filings’ (RNS) category.
2026-05-26 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings Classification · 88% confidence The document is a compliance letter submitted to BSE and NSE under SEBI (Substantial Acquisition of Shares and Takeovers) Regulation 31(4) declaring promoter shareholdings and absence of encumbrances. It is not announcing a report or providing financial statements, nor does it involve a threshold crossing or insider trading transaction. This is a routine regulatory compliance filing under SEBI rules, fitting the “Regulatory Filings” (RNS) category.
2026-05-26 English
Annual Secretarial Compliance Report for the Financial Year 2025-2026.
Regulatory Filings Classification · 90% confidence The document is an Annual Secretarial Compliance Report submitted under SEBI LODR Regulation 24A, consisting of a detailed external compliance certificate issued by Practising Company Secretaries. It does not contain financial statements or management analysis, nor is it a proxy/material for shareholders voting or a financial report like an Annual Report or Interim Report. It is a regulatory compliance attestation (officer certification), which per the Certification Rule should be classified as a general Regulatory Filing.
2026-05-22 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 93% confidence The document is an official intimation under SEBI Takeover Regulations disclosing a substantial acquisition of shares (34.26% stake) by Valiant Organics Ltd. from Dhanvallabh Ventures LLP, complying with Regulation 10(5) of the Substantial Acquisition of Shares and Takeovers Regulations. This is a statutory notification of change in significant shareholding levels, matching the definition of Major Shareholding Notification.
2026-05-20 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.